Tanabe Pharma America, Inc.
Clinical trials sponsored by Tanabe Pharma America, Inc., explained in plain language.
-
ALS drug trial halted: oral Edaravone's promise unfulfilled
Disease control TerminatedThis study tested an oral form of edaravone in 384 adults with ALS to see if it could slow the disease's progression over 48 weeks. Participants were randomly assigned to different dosing schedules. The trial was terminated early, and results are not yet fully available.
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
ALS drug trial halted early: what we know about oral edaravone
Disease control TerminatedThis study tested two doses of oral edaravone in 202 people with ALS to see if it could slow disease progression. Participants were followed for up to 48 weeks. The trial was terminated early, so the full results are not available.
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Early safety check for new drug MT-6345 in healthy people
Knowledge-focused TerminatedThis early-phase study tested the safety and how the body handles a new drug called MT-6345 in 52 healthy adults. Participants received either the drug or a placebo, and researchers monitored for side effects and drug levels in the blood. The study was terminated early, so result…
Phase: PHASE1 • Sponsor: Tanabe Pharma America, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC